Celgene Corporation, Former Chairman
Dr. Barer is the Former Chairman and CEO of Celgene. He was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and Executive Chairman subsequently until January 1, 2011 when he transitioned to his current position. Previously he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/ General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990.
Dr Barer joined the Celanese Research Company in 1974 and formed the Biotechnology group that was subsequently spun out to form Celgene.
Dr. Barer holds numerous professional awards including the “Lifetime Achievement Award” (International Myeloma Foundation), “Outstanding Individual Award” (The Biotech Meeting 2010), “Dream & Promise Award” (Children’s Brain Tumor Foundation) “Odyssey Award” (Center for Medicine in the Public Interest), the “Corporate Vision Award” (Gilda’s Club), the “Sparkle of Hope Award” (Community Hope), “Master Entrepreneur Award” (Ernst & Young), “The Hall of Distinguished Alumni Award” (Rutgers University Alumni Federation), “Dr. Sol J. Barer Award for Vision, Innovation and Leadership” (BioNJ), “Science and Technology Industry Medal” (R&D Council of NJ), “Rutgers University Graduate School Annual Distinguished Alumnus Award”, “Winthrop-Sears Medal” (The Chemists Club and the Chemical Heritage Foundation), and “Albert Einstein Award in Life Sciences” (Global Capital Associates and Jerusalem Fund, Israel), “DART/NYU Biotechnology Achievement Award in Applied Biotechnology” (Biotechnology Study Center of the New York University School of Medicine).
Dr. Barer serves as Chairman of the Board of Cerecor, Chairman of the Board of ContraFect, Chairman of the Board of Edge Therapeutics, Chairman of the Board of InspireMD, Chairman of the Board of RestorGenex and Chairman of the Board of Medgenics and is on the Board of Directors of Aegerion Pharmaceuticals and Amicus Therapeutics. He serves as an advisor to biotechnology/medical companies. He served as Chair of the Board of BioNJ from 2010-2012, was Chairman of the University of Medicine and Dentistry of New Jersey Governor’s Advisory Committee, served as a Commissioner of the NJ Commission on Science and Technology and was a member of the Board of Trustees of Rutgers – The State University of New Jersey.
Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University and B.S. from Brooklyn College.